Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: A pooled analysis across phase III and long-term extension studies
Arthritis Care & Research Oct 05, 2019
Gladman DD, Charles-Schoeman C, McInnes IB, et al. - A total of 783 tofacitinib-treated patients were involved in this study in order to assess cardiovascular disease (CVD) risk factors and major adverse cardiovascular events (MACE) in patients with active psoriatic arthritis (PsA) who were receiving tofacitinib 5 or 10 mg twice daily plus conventional synthetic disease-modifying antirheumatic drugs, since tofacitinib raises circulating lipid levels in some patients. In LDL cholesterol (LDL-c) and HDL cholesterol (HDL-c), percentage progress from baseline levels varied from 9% to 14% for tofacitinib 5 mg and 10 mg at 3 and 6 months and no significant modifications in LDL-c: HDL-c or total cholesterol: HDL-c ratios were noted. Blood pressure remained stable for 24 months. Fifty-eight individuals had hypertension-related adverse events (AEs) and none were lethal. Five individuals had MACE, of which, two were lethal. Therefore, serum lipid level rises at month 3 after tofacitinib treatment in PsA were constant with remarks in rheumatoid arthritis and psoriasis. Moreover, the incidence rate of hypertension-related AEs and MACE was profound and long-term follow-up is continuing.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries